why do glp 1 drugs cause hair loss GLP-1 therapies and loss: A systematic review of current evidence and implications for counseling The Truth About GLP-1 Drugs

Accessibility and affordability of these medications are critical concerns, particularly in low- and middle-income countries where obesity prevalence is rising

DPP-4 inhibitors prevent enhancing insulin secretion, incretin degradation, and reducing glucagon release for better glucose control 3.1

Cutaneous adverse events (CAEs) to GLP-1 agonists were retrospectively reviewed using the FDA Adverse Event Reporting System (FAERS)

Many of these involved first time use error secondary to misunderstanding of how to use the injection pen ( n = 32, 21%)

Stucky, Monitoring Report: GLP-1 RA Prescribing Trends March 2025 Data

SGLT-2 inhibitors were superior to GLP-1RA in reducing the risk of HHF and the renal outcome (24% and 22% lower risk, respectively)